The fungal cell wall as a drug target.
Fungal infections are increasingly common and, in certain vulnerable patients, can be serious and even life threatening. The fungal cell wall, a structure with no mammalian counterpart, presents an attractive therapeutic target. Inhibitors of the synthesis of one cell-wall component, beta-(1,3)-glucan, are currently under development as antifungal and antipneumocystis agents.
Georgopapadakou
N H
NH
Dept of Oncology, Roche Research Center, Nutley, NJ 07110, USA.
Tkacz
J S
JS
D000935:Antifungal Agents / Q000494:pharmacology*; D002240:Carbohydrate Sequence; D002473:Cell Wall / Q000187:drug effects*; D002686:Chitin / Q000096:biosynthesis; D002687:Chitin Synthase / Q000037:antagonists & inhibitors*; D005936:Glucans / Q000096:biosynthesis; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors*; D008969:Molecular Sequence Data; D009181:Mycoses / Q000188:drug therapy*; D047071:beta-Glucans
D000935:Antifungal Agents; D005936:Glucans; D047071:beta-Glucans; D002686:Chitin; C033363:beta-1,3-glucan; D005964:Glucosyltransferases; C040232:glucan synthase; D002687:Chitin Synthase